Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

Table 1 Patient characteristics in the two-drug (palonosetron+DEX) and three-drug (NK1RA + palonosetron+DEX) groups before and after a propensity score-matching

	Two-drug before matching	Three-drug before matching	p value	Two-drug after matching	Three-drug after matching	p value
Case number	97	215		97	97
Age (mean ± SD)	66.4 ± 9.9	63.2 ± 11.2	0.011	66.4 ± 9.9	64.7 ± 9.5	0.49
Sex (M/F), n (%)	45/52	103/112	0.80	45/52	37/60	0.24
Sex (M/F), n (%)	(46.4/53.6)	(47.9/52.1)	0.80	(46.4/53.6)	(38.1/61.9)	0.24
ECOG PS0/1,2, n (%)	54/43	96/119	0.07	54/43	51/46	0.67
ECOG PS0/1,2, n (%)	(55.7/44.3)	(44.7/55.3)	0.07	(55.7/44.3)	(51.5/48.5)	0.67
Primary organ, n (%) Colon/Ovary+Uterus/Lung/Stomach	56/16/14/11	155/37/9/14	0.003	56/16/14/11	57/24/7/9	0.24
Primary organ, n (%) Colon/Ovary+Uterus/Lung/Stomach	(57.7/16.5/14.4/11.3)	(72.1/17.2/4.2/6.5)	0.003	(57.7/16.5/14.4/11.3)	(58.8/24.7/7.2/9.3)	0.24
Type of anticancer drugs, n (%) L-OHP/CBDCA/CPT-11	46/28/23	132/46/37	0.07	46/28/23	52/31/14	0.26
Type of anticancer drugs, n (%) L-OHP/CBDCA/CPT-11	(47.4/28.9/23.7)	(61.4/21.4/17.2)	0.07	(47.4/28.9/23.7)	(53.6/33.0/14.4)	0.26
Sequence of chemotherapy, n (%) 1st course/2nd-3rd courses	39/58	88/127	0.90	39/58	45/52	0.38
Sequence of chemotherapy, n (%) 1st course/2nd-3rd courses	(40.2/59.8)	(40.9/59.1)	0.90	(40.2/59.8)	(46.4/53.6)	0.38
Additional oral DEX on day 2–3 of chemotherapy, n (%)	9 (9.3)	30 (14.0)	0.25	9 (9.3)	12 (12.4)	0.49

NK1RA neurokinin 1 receptor antagonist, DEX dexamethasone, M male, F female, PS performance status, L-OHP oxaliplatin, CBDCA carboplatin, CPT-11 irinotecan, SD standard deviation

ISSN: 2050-6511